Experience in the diagnosis and treatment of a drug-induced pemphigus

doi:10.7518/hxkq.2021.06.016

West China Journal of Stomatology ›› 2021, Vol. 39 ›› Issue (6): 724-727.doi: 10.7518/hxkq.2021.06.016

Previous Articles Next Articles

Experience in the diagnosis and treatment of a drug-induced pemphigus

Yuan Peiyang¹(), Qiu Min¹^,², Wan Zixin³, Jiang Lu¹()

^1.State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & Dept. of Oral Medicine, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China
^2.Dept. of Oral Medicine, Stomatology Center, Shenzhen People, s Hospital, Shenzhen 518020, China
^3.State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & Dept. of Oral Pathology, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China

Received:2020-09-11 Revised:2021-05-18 Online:2021-12-01 Published:2021-12-03
Contact: Jiang Lu E-mail:yuanpeiyangvip@163.com;jianglu@scu.edu.cn
Supported by:
The National Natural Science Foundation of China(81670998)

Abstract

Abstract:

Drug-induced pemphigus (DIP) is a special type of pemphigus, and its pathogenesis, characteristics of treatment, and prognosis are closely related to the inducing drugs. This article reports the diagnosis and treatment of DIP (pemphigus vulgaris) caused by the administration of rifampin to a patient with tuberculosis. Combined with the literature, we discussed the types, pathogenesis, differential diagnosis, and treatment principles of DIP. We propose that in the oral clinical practice for patients with pemphigus vulgaris, the importance of investigating suspected drugs that induce DIP should be emphasized.

Key words: drug-induced pemphigus, rifampin, pemphigus vulgaris, tuberculosis

CLC Number:

R 781.5

Yuan Peiyang, Qiu Min, Wan Zixin, Jiang Lu. Experience in the diagnosis and treatment of a drug-induced pemphigus[J]. West China Journal of Stomatology, 2021, 39(6): 724-727.

Figures/Tables 2

References 22

1	Ioannides D, Lazaridou E, Rigopoulos D. Pemphigus[J]. J Eur Acad Dermatol Venereol, 2008, 22(12): 1478-1496.
2	Brenner S, Goldberg I. Drug-induced pemphigus[J]. Clin Dermatol, 2011, 29(4): 455-457.
3	Tavakolpour S. Pemphigus trigger factors: special focus on pemphigus vulgaris and pemphigus foliaceus[J]. Arch Dermatol Res, 2018, 310(2): 95-106.
4	Pile HD, Crane JS. Drug induced pemphigus[M]. Treasure Island (FL): StatPearls Publishing, 2019.
5	龚旺, 魏子豪, 陈谦明, 等. 药物诱发性天疱疮[J]. 口腔医学, 2016, 36(9): 769-773.
	Gong W, Wei ZH, Chen QM, et al. Drug induced pemphigoid[J]. Stomatology, 2016, 36(9): 769-773.
6	Newby CS, Barr RM, Greaves MW, et al. Cytokine release and cytotoxicity in human keratinocytes and fibroblasts induced by phenols and sodium dodecyl sulfate[J]. J Invest Dermatol, 2000, 115(2): 292-298.
7	Palleria C, Bennardo L, Dastoli S, et al. Angiotensin-converting-enzyme inhibitors and angiotensinⅡreceptor blockers induced pemphigus: a case series and literature review[J]. Dermatol Ther, 2019, 32(1): e12748.
8	Hayashida MZ, Pinheiro JR, Enokihara M, et al. Biologic therapy-induced pemphigus[J]. An Bras Dermatol, 2017, 92(4): 591-593.
9	Saito Y, Hayashi S, Yamauchi A, et al. Tracing the origins of active amide group-positive drug-induced pemphigus vulgaris along the Silk Road: a case report of candesartan-induced pemphigus vulgaris and review of nonthiol drug-induced pemphigus[J]. Int J Dermatol, 2018, 57(11): e131-e134.
10	Yoshimura K, Ishii N, Hamada T, et al. Clinical and immunological profiles in 17 Japanese patients with drug-induced pemphigus studied at Kurume University[J]. Br J Dermatol, 2014, 171(3): 544-553.
11	Kardaun SH, Maehara LD. Drug-induced pemphigus [M]//Jonkman MF. Autoimmune bullous diseases: text and review. Cham: Springer International Publishing, 2016: 107-110.
12	Brenner S, Bialy-Golan A, Ruocco V. Drug-induced pemphigus—immunoglobulins from this patient induced pla-sminogen activator synthesis by human epidermal cells in culture: mechanism for acantholysis in pemphigus[J]. Clin Dermatol, 1998, 16(3): 393-397.
13	Pisani M, Ruocco V. Drug-induced pemphigus[J]. Clin Dermatol, 1986, 4(1): 118-132.
14	Suying F, Wuqing Z, Jiechen Z, et al. Analysis of 6 cases of drug-induced pemphigus[J]. Eur J Dermatol, 2011, 21(5): 696-699.
15	Miyagawa S, Yamashina Y, Okuchi T, et al. Exacerbation of pemphigus by rifampicin[J]. Br J Dermatol, 1986, 114(6): 729-732.
16	Lee CW, Lim JH, Kang HJ. Pemphigus foliaceus indu-ced by rifampicin[J]. Br J Dermatol, 1984, 111(5): 619-622.
17	Goldberg I, Ingher A, Brenner S. Pemphigus vulgaris triggered by rifampin and emotional stress[J]. Skinmed, 2004, 3(5): 294.
18	Gange RW, Rhodes EL, Edwards CO, et al. Pemphigus induced by rifampicin[J]. Br J Dermatol, 1976, 95(4): 445-448
19	李冠群, 罗斌. 利福平诱发并加重的落叶型天疱疮1例[J]. 临床皮肤科杂志, 1995, 24(5): 318-319.
	Li GQ, Luo B. Pemphigoid foliaceus induced and exacerbated by rifampicin: a case report[J]. J Chin Dermatol, 1995, 24(5): 318-319.
20	Lee KH, Shin JG, Chong WS, et al. Time course of the changes in prednisolone pharmacokinetics after co-administration or discontinuation of rifampin[J]. Eur J Clin Pharmacol, 1993, 45(3): 287-289.
21	McAllister WA, Thompson PJ, Al-Habet SM, et al. Rifampicin reduces effectiveness and bioavailability of prednisolone[J]. Br Med J (Clin Res Ed), 1983, 286(6369): 923-925.
22	陈金波, 刘洁, 王宝玺. 利福平对糖皮质激素治疗大疱性类天疱疮的干扰[J]. 临床皮肤科杂志, 2009, 38(4): 239-241.
	Chen JB, Liu J, Wang BX. Glucocorticoids-treated bullous pemphigoid interfered by rifampicin: a case report [J]. J Chin Dermatol, 2009, 38(4): 239-241.

[1]	Feng Hui, Luo Xiaobo, Jiang Lu, Chen Qianming.. Patient with pemphigus vulgaris complicated with dysfunctional uterine bleeding upon glucocorticoid usage: a case report [J]. West China Journal of Stomatology, 2015, 33(2): 218-220.
[2]	. [J]. West China Journal of Stomatology, 2003, 21(02): 164-164.

Experience in the diagnosis and treatment of a drug-induced pemphigus

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 2

References 22

Related Articles 2

Recommended Articles

Metrics

Comments